CTLA4 and melanoma: The combination of ipilimumab (IPI; anti–CTLA-4) and nivolumab (anti–PD-1) demonstrates superior response and survival in melanoma compared with single-agent nivolumab or IPI and, therefore, has become the preferred first-line regimen for many patients with advanced disease (1).